Publications by authors named "Peter A Henriksen"

Claim this Profile
C
Challenges of Clinical Trials in Cardio-Oncology: Navigating Surrogate Outcomes and Identifying Patients at Risk of Late Cardiovascular Complications.
Peter A Henriksen

Circulation· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracycline Dose, Myocardial Injury, and Change in Left Ventricular Function in the Cardiac CARE Trial.
Krithika Loganath, Kuan Ken Lee, Olga Oikonomidou, Peter Hall, Nicholas L Mills, Peter A Henriksen

JACC CardioOncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response by Henriksen et al Regarding Article, "Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial".
Peter A Henriksen, Peter Hall, Ninian N Lang

Circulation· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute chest pain in a young man with low cardiovascular risk profile.
Jasper Boeddinghaus, Andrew R Chapman, Peter A Henriksen

Heart· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.
Peter A Henriksen, Peter Hall, Iain R MacPherson, Shruti S Joshi, Trisha Singh

Circulation· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: Primer.
Peter A Henriksen, Stephen Rankin, Ninian N Lang

JACC CardioOncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Peter A Henriksen, Peter Hall, Olga Oikonomidou, Iain R MacPherson, Morag Maclean

Circ Heart Fail· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial.
Mandeep S Sidhu, Karen P Alexander, Zhen Huang, Sean M O'Brien, Bernard R Chaitman, Peter A Henriksen

Am Heart J· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Radek Pudil, Christian Mueller, Jelena Čelutkienė, Peter A Henriksen, Dan Lenihan

Eur J Heart Fail· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intravascular Healing Is Not Affected by Approaches in Contemporary CTO PCI: The CONSISTENT CTO Study.
Simon J Walsh, Colm G Hanratty, Margaret McEntegart, Julian W Strange, Johannes Rigger, Peter A Henriksen

JACC Cardiovasc Interv· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Peter A Henriksen

Heart· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Ferumoxytol-enhanced magnetic resonance imaging in acute myocarditis.
Colin G Stirrat, Shirjel R Alam, Thomas J MacGillivray, Calum D Gray, Marc R Dweck, Peter A Henriksen

Heart· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myocardial inflammation, injury and infarction during on-pump coronary artery bypass graft surgery.
Shirjel R Alam, Colin Stirrat, Nick Spath, Vipin Zamvar, Renzo Pessotto, Peter A Henriksen

J Cardiothorac Surg· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Ferumoxytol-enhanced magnetic resonance imaging assessing inflammation after myocardial infarction.
Colin G Stirrat, Shirjel R Alam, Thomas J MacGillivray, Calum D Gray, Marc R Dweck, Peter A Henriksen

Heart· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computed tomography myocardial perfusion vs O-water positron emission tomography and fractional flow reserve.
Michelle C Williams, Saeed Mirsadraee, Marc R Dweck, Nicholas W Weir, Alison Fletcher, Peter A Henriksen

Eur Radiol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Ferumoxytol-enhanced magnetic resonance imaging methodology and normal values at 1.5 and 3T.
Colin G Stirrat, Shirjel R Alam, Thomas J MacGillivray, Calum D Gray, Rachael Forsythe, Peter A Henriksen

J Cardiovasc Magn Reson· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The potential of neutrophil elastase inhibitors as anti-inflammatory therapies.
Peter A Henriksen

Curr Opin Hematol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium.
Shirjel R Alam, David E Newby, Peter A Henriksen

Biochem Pharmacol· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transient global amnesia as the presenting feature of heparin-induced thrombocytopenia.
Chun Huat Teh, Martyn N Robertson, Theodore E Warkentin, Peter A Henriksen, Edward T Brackenbury

J Card Surg· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human neutrophil elastase: mediator and therapeutic target in atherosclerosis.
Peter A Henriksen, Jean-Michel Sallenave

Int J Biochem Cell Biol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of upper gastrointestinal haemorrhage complicating dual anti-platelet therapy.
Peter A Henriksen, Kelvin Palmer, Nick A Boon

QJM· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene delivery of the elastase inhibitor elafin protects macrophages from neutrophil elastase-mediated impairment of apoptotic cell recognition.
Peter A Henriksen, Andrew Devitt, Yuri Kotelevtsev, Jean-Michel Sallenave

FEBS Lett· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adenoviral gene delivery of elafin and secretory leukocyte protease inhibitor attenuates NF-kappa B-dependent inflammatory responses of human endothelial cells and macrophages to atherogenic stimuli.
Peter A Henriksen, Mary Hitt, Zhou Xing, Jun Wang, Chris Haslett

J Immunol· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis